Nation's evolving role in global pharma enhanced

Samsung Epis Holdings has opened its first biopharmaceutical research and development center in China focused on antibody-drug conjugates, or ADCs, joining a growing list of multinational drugmakers deepening their presence in a country that has become one of the world's most active hubs for cancer drug innovation.

Raccontata daglobal.chinadaily.com.cn